WASHINGTON -- Continuing use of rivaroxaban (Xarelto) at either 20 mg or 10 mg dose appears to reduce the risk of recurrent venous thromboembolism without increasing the risk for bleeding. "This is a ...

June 29, 2007 (Perugia, Italy) - Promising phase 2 results with the new oral direct factor Xa inhibitor anticoagulant rivaroxaban (Bayer) in the treatment of patients with deep vein thrombosis (DVT) ...

LOS ANGELES, CA—Another real-world study has suggested that there may be differences among the non-vitamin K antagonist oral anticoagulants (NOACs) in terms of the risk of major bleeding. Among ...

Indoco Remedies Ltd., a fully integrated, research-oriented pharmaceutical company, announced final approval of the company’s Abbreviated New Drug Application (ANDA) for rivaroxaban tablets USP, 2.5 ...

WASHINGTON, DC (updated with commentary) — In patients with venous thromboembolism (VTE) who had completed 6 to 12 months of anticoagulation therapy but for whom it was uncertain as to whether ...

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for rivaroxaban ...

The FDA approved the anticoagulant rivaroxaban (Xarelto, Janssen), to reduce the risk for stroke among patients with non-valvular atrial fibrillation (AF). Approval comes after data from the ROCKET-AF ...

Rivaroxaban shows superiority to standard therapy in net clinical benefit, a secondary endpoint of the study / Rivaroxaban well tolerated in this long-term trial / Full data set to be presented at Hot ...

Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke. (HealthDay News) — Subcutaneous injection of abelacimab results ...

The ROCKET-AF trial was designed as double-blind, double dummy trial comparing rivaroxaban (20 mg or 15 mg once a day) with warfarin (target INR of 2.0 to 3.0) for the prevention of stroke and ...

Therapeutic-dose anticoagulation primarily consisting of rivaroxaban (Xarelto; Bayer/Janssen), compared with standard thromboprophylaxis, does not improve outcomes in patients hospitalized with ...

The Appraisal Committee considered evidence submitted by the manufacturer of rivaroxaban and a review of this submission by the Evidence Review Group (ERG). The main clinical effectiveness evidence ...